Chimeron Bio announced it raised $12.8 Million in an amended filing

Company

Location

About

Chimeron Bio is an early-stage biotech company focused on breakthrough treatments of cancer. Chimeron’s patented Multiplex nanoparticle and self-amplifying mRNA technology enables delivery of multiple genes to transform the complex tumor micro-environment with a unique “All-in-One” treatment approach. Chimeron is developing a high-impact pipeline for the creation and delivery therapeutics with the potential for meaningful patient results.